PUBLISHER: Grand View Research | PRODUCT CODE: 1493329
PUBLISHER: Grand View Research | PRODUCT CODE: 1493329
The U.S. facial injectable market is anticipated to reach USD 8.02 billion by 2030, exhibiting a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing acceptance of aesthetic procedures and the increasing geriatric population are some of the major factors driving the market growth.
The increasing geriatric population of the U.S. is increasing the demand for the development of minimally invasive surgical procedures. Facial injectable offer an alternative to several aesthetic surgical procedures. Moreover, these procedures offer several advantages, such as less pain, less trauma, lesser blood loss, and faster recovery. In addition, the increasing focus of market players on developing demand-specific solutions with lesser allergy risk significantly contributes to the market growth.
The increasing awareness about aesthetic procedures owing to the rising focus on facial appearance further drives the market growth. Moreover, the availability of facial injectable to address different demands of patients has increased their demand in different age groups as per their needs. For instance, according to the 2022 Plastic Surgery Statistics Report of The American Society of Plastic Surgeons, the number of neuromodulator injection procedures in the age group of 30 to 39 and 40 to 54 in 2022 has increased by 70% and 74% from 2019 simultaneously. Similarly, the number of HA filler procedures in the age group of 30 to 39 and 40 to 54 in 2022 has increased by 69% and 70% from 2019 simultaneously. This increasing demand for facial injectable in different age groups is expected to drive market growth over the forecast period.